Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04201873 |
|
Recruitment Status :
Recruiting
First Posted : December 17, 2019
Last Update Posted : May 2, 2024
|
Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Phase One Foundation
Oncovir, Inc.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 1, 2024 |
| Estimated Study Completion Date : | August 1, 2025 |